iX Biopharma Ltd. (SGX:42C)
Singapore flag Singapore · Delayed Price · Currency is SGD
0.182
-0.009 (-4.71%)
Mar 9, 2026, 5:04 PM SGT

iX Biopharma Ratios and Metrics

Millions SGD. Fiscal year is Jul - Jun.
Fiscal Year
CurrentFY 2025 FY 2024 FY 2023 FY 2022 FY 2021 2020 - 2016
Period Ending
Mar '26 Jun '25 Jun '24 Jun '23 Jun '22 Jun '21 2020 - 2016
Market Capitalization
189142270122167
Upgrade
Market Cap Growth
871.14%-36.24%-68.05%-43.05%-26.84%3.17%
Upgrade
Enterprise Value
190172262111162
Upgrade
PS Ratio
26.111.833.7411.798.5195.91
Upgrade
PB Ratio
45.6538.925.134.406.2014.29
Upgrade
P/TBV Ratio
48.68149.555.514.486.3114.81
Upgrade
P/FCF Ratio
----41.89-
Upgrade
P/OCF Ratio
----39.21-
Upgrade
EV/Sales Ratio
26.242.203.7310.517.7092.74
Upgrade
EV/EBITDA Ratio
----96.40-
Upgrade
EV/EBIT Ratio
----221.09-
Upgrade
EV/FCF Ratio
-49.76---37.89-
Upgrade
Debt / Equity Ratio
1.6316.171.200.270.220.36
Upgrade
Debt / EBITDA Ratio
----2.91-
Upgrade
Debt / FCF Ratio
----1.51-
Upgrade
Net Debt / Equity Ratio
0.2313.610.77-0.14-0.46-0.17
Upgrade
Net Debt / EBITDA Ratio
-0.18-0.85-0.470.24-7.990.18
Upgrade
Net Debt / FCF Ratio
-0.25-1.25-0.490.26-3.140.22
Upgrade
Asset Turnover
0.500.600.300.220.610.10
Upgrade
Inventory Turnover
5.464.984.213.862.092.14
Upgrade
Quick Ratio
0.910.320.651.341.982.19
Upgrade
Current Ratio
1.050.470.891.532.142.55
Upgrade
Return on Equity (ROE)
-155.52%-431.07%-106.91%-54.02%-29.23%-75.27%
Upgrade
Return on Assets (ROA)
-24.84%-30.32%-23.69%-22.32%1.32%-39.86%
Upgrade
Return on Capital Employed (ROCE)
-72.70%-272.70%-103.50%-53.80%2.40%-75.20%
Upgrade
Earnings Yield
-3.15%-71.38%-48.44%-13.79%-3.75%-4.92%
Upgrade
FCF Yield
-2.02%-27.87%-30.64%-11.98%2.39%-5.32%
Upgrade
Buyback Yield / Dilution
-9.14%-14.25%-0.33%-2.51%-7.60%-7.13%
Upgrade
Source: S&P Capital IQ. Standard template. Financial Sources.